Framing upcoming Mevro Ph3 prostate cancer data

Research evidence excerpt

Framing upcoming Mevro Ph3 prostate cancer data

Idea

July 27, 2026 04:14 AM GMT

Morgan Stanley & Co. LLCMPfizer Inc | North America Terence C Flynn, Ph.D.

Equity Analyst

Framing upcoming Mevro Ph3 Terence.Flynn@morganstanley.comDamien H Kerner +1 212 761-2230

Research Associate

Damien.H.Kerner@morganstanley.com +1 212 761-3829

prostate cancer data Alexander Yevdokimov, Ph.D.

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

We expect topline data from the first Ph3 prostate cancer trial Hailey Horowitz

of mevrometostat (mevro, EZH2i) later this year. We see this as Research Associate

Hailey.Horowitz@morganstanley.com +1 212 761-5264

the next key pipeline catalyst for PFE shares following the Chris Yu, J.D., Ph.D.

recent setback for SV in lung cancer. EquityChris.L.Yu@morganstanley.comAnalyst +1 212 761-2535

Connor M Massari

Mevrometostat (Mevro) Ph3 prostate cancer data is the next pipeline catalyst Equity Analyst

for PFE shares. Mevro is an oral EZH2 inhibitor in development for metastatic Connor.Massari@morganstanley.com +1 212 761-2417

castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive Morgan Stanley India Company Private Limited+

prostate cancer (mCSPC), being evaluated in combination with PFE's Xtandi Saket Agarwal

(androgen receptor inhibitor) across three Ph3 studies - MEVPRO-1 (LINK), Saket.Agarwal@morganstanley.com +91 22 6995-4012

MEVPRO-2 (LINK) and MEVPRO-3 (LINK). MEVPRO-1 and 2 carry PCD's of July 2026

and Dec 2026 respectively, while MEVPRO-3 carries a PCD of Sept 2028. PFE Pfizer Inc (PFE.N, PFE UN)

guided to a 2H26 readout for MEVPRO-1 and has not yet provided guidance for Major Pharmaceuticals | United States of America

Stock Rating Equal-weight

MEVPRO-2 or MEVPRO-3. While MEVPRO-1 will read out first, MEVPRO-2